MedTrace Logo

Pilot Study on the Use of Hydrocortisone, Vitamin c and Tiamine in Patient With Sepsis and Septic Shock

NCT04111822 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-10-06

No results posted yet for this study

Summary

Due to the high incidence, mortality and short and long term complications of sepsis and septic shock, it is necessary to look for strategies to try to minimize this impact.

Conditions

Interventions

DRUG

red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate

Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving

DRUG

on crystalloid fluid and Tranexamic acid

Resuscitation with crystalloids, Performing culture battery, antibiotic therapy

Sponsors & Collaborators

  • Cristina Martinez

    lead OTHER

Principal Investigators

  • Juliana Gonzalez, MD · Hospital Dr Josep Trueta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04111822 on ClinicalTrials.gov